Glenveagh Properties PLC (LON:GLV)

Orchard Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	869.2	607.94	644.71	476.81	232.3
Revenue Growth (YoY)	42.98%	-5.70%	35.21%	105.26%	-18.39%
Cost of Revenue	685.28	495.21	536.66	393.75	222.82
Gross Profit	183.92	112.73	108.05	83.06	9.48
Selling, General & Admin	48.98	39.38	36.06	32.49	22.19
Operating Expenses	51.78	41.78	37.96	32.49	22.19
Operating Income	132.14	70.95	70.1	50.57	-12.71
Interest Expense	-19.02	-16.22	-7.09	-4.85	-3.03
Other Non Operating Income (Expenses)	0.69	0.38	-	-	-
EBT Excluding Unusual Items	113.82	55.11	63	45.72	-15.75
Pretax Income	113.82	55.11	63	45.72	-15.75
Income Tax Expense	16.06	8	10.43	8.02	-1.84
Net Income	97.76	47.11	52.57	37.7	-13.9
Net Income to Common	97.76	47.11	52.57	37.7	-13.9
Net Income Growth	107.51%	-10.38%	39.43%	-	-
Shares Outstanding (Basic)	577	589	694	841	871
Shares Outstanding (Diluted)	580	590	696	846	871
Shares Change (YoY)	-1.74%	-15.21%	-17.71%	-2.93%	-
EPS (Basic)	0.17	0.08	0.08	0.04	-0.02
EPS (Diluted)	0.17	0.08	0.08	0.04	-0.02
EPS Growth	111.29%	5.58%	68.93%	-	-
Free Cash Flow	-95.28	34.5	121.58	88.6	-15.52
Free Cash Flow Per Share	-0.16	0.06	0.17	0.10	-0.02
Gross Margin	21.16%	18.54%	16.76%	17.42%	4.08%
Operating Margin	15.20%	11.67%	10.87%	10.61%	-5.47%
Profit Margin	11.25%	7.75%	8.15%	7.91%	-5.99%
Free Cash Flow Margin	-10.96%	5.67%	18.86%	18.58%	-6.68%
EBITDA	133.21	71.95	71.01	51.4	-12.1
EBITDA Margin	15.33%	11.83%	11.01%	10.78%	-5.21%
D&A For EBITDA	1.07	1	0.91	0.83	0.61
EBIT	132.14	70.95	70.1	50.57	-12.71
EBIT Margin	15.20%	11.67%	10.87%	10.61%	-5.47%
Effective Tax Rate	14.11%	14.52%	16.56%	17.54%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.